Adamas Pharmaceuticals Inc (ADMS) Drops 6.21% on January 11

Equities Staff |

Adamas Pharmaceuticals Inc (ADMS) was one of the Russell 2000's biggest losers for Monday January 11 as the stock slid 6.21% to $22.96, a loss of $-1.52 per share. Starting at an opening price of $24.33 a share, the stock traded between $22.50 and $24.71 over the course of the trading day. Volume was 337,255 shares over 3,312 trades, against an average daily volume of 289,038 shares and a total float of 18.42 million.

The losses send Adamas Pharmaceuticals Inc down to a market cap of $422.97 million. In the last year, Adamas Pharmaceuticals Inc has traded between $31.84 and $12.73, and its 50-day SMA is currently $18.37 and 200-day SMA is $19.77.

Adamas Pharmaceuticals Inc is a specialty pharmaceutical company, is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. Its portfolio includes Namzaric and Namenda XR.

Adamas Pharmaceuticals Inc is based out of Emeryville, CA and has some 59 employees. Its CEO is Gregory Went.

For a complete fundamental analysis analysis of Adamas Pharmaceuticals Inc, check out Equities.com’s Stock Valuation Analysis report for ADMS. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.



DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

GSV Capital Corp

GSV Capital Corp is an externally managed, non-diversified closed-end management investment company. The Company has elected to be treated as a business development company.

Private Markets

Ozobot by Evollve Inc

Ozobot is a world leader in compact super intelligent robots that entertain and educate through fun interactive gaming.

WayBetter

The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…